Navigation Links
CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008
Date:10/23/2008

PALO ALTO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that it will release third quarter financial results for 2008 after the market closes on Thursday, November 6, 2008. Company management will webcast a conference call at 5:00 p.m. EST, 2:00 p.m. PST, on the company's website.

To access the live webcast, please log on to the Company's website at http://www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6241, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Thursday, November 13, 2008. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 68392680.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(R) (regadenoson) injection for use as a pharmacologic str
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  Four-dimensional (4-D) printing develops ... on external stimuli such as changes in temperature. ... disruptive effect in multiple industries.  In the near ... by printing objects ranging from human organs to ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... Wednesday of last week RENU 28, the world's first and ... for purchase in Australia and New Zealand, and the response ... is, if you think about the definition of aging, it's ... within your body. If you think about the definition of ... What RENU 28 does is it works with these tiny ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, ... host a conference call to provide an update ... p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and ... Live web cast: www.neurotropebioscience.com , under "Investor Relations"The ... after completion through September 2, 2014 at (888) ...
(Date:8/20/2014)... Toronto, Canada (PRWEB) August 20, 2014 ... wisdom that E&L studies should be performed late in ... system is known. But current regulatory trends suggest that, ... are on the rise. In recent years, multiple drug ... E&L packages or address specific questions during phase I/II. ...
Breaking Biology Technology:Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... LSU associate professor of chemistry in the College of ... honor for scientists and engineers in the early stages ... Award for Scientists and Engineers, or PECASE. "I ... award. LSU is a rich environment for accomplishing nanoscience ...
... ... ... ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... ... ... var shortURL = ... need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var ...
Cached Biology Technology:LSU’s Jayne Garno receives early career award from President 2Atrium Innovations Announces Third Quarter Financial Results of 2010 2Atrium Innovations Announces Third Quarter Financial Results of 2010 3Atrium Innovations Announces Third Quarter Financial Results of 2010 4Atrium Innovations Announces Third Quarter Financial Results of 2010 5Atrium Innovations Announces Third Quarter Financial Results of 2010 6Atrium Innovations Announces Third Quarter Financial Results of 2010 7Atrium Innovations Announces Third Quarter Financial Results of 2010 8Atrium Innovations Announces Third Quarter Financial Results of 2010 9Atrium Innovations Announces Third Quarter Financial Results of 2010 10Atrium Innovations Announces Third Quarter Financial Results of 2010 11Atrium Innovations Announces Third Quarter Financial Results of 2010 12Atrium Innovations Announces Third Quarter Financial Results of 2010 13Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 2Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 3Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 4Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 5Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 6Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 7Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 8
(Date:8/21/2014)... SHELTON, Conn. , Aug. 21, 2014 ... on the growing mobile commerce market, announced today that ... purchase common stock to be issued in its proposed ... been approved for listing on The Nasdaq Capital Market, ... of the common stock and warrants, and will trade ...
(Date:8/21/2014)... A landmark study aimed at improving the food intake, ... long-term care homes is among three projects at the ... grants from the Canadian Institutes of Health Research (CIHR). ... Applied Health Sciences at Waterloo, and a Schlegel research ... two years to investigate why many Canadians living in ...
(Date:8/21/2014)... Saturday to Wednesday, Oct. 18-22, 2014 , ... Harbor Drive, San Diego, CA 92101 , ... other presentations of the latest research in human ... session featuring high-scoring abstracts on rare genetic variants ... cancers, and treatment for sun sensitivity (Saturday, Oct. ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2
... that resists infection, yet 10% of the world's agricultural ... fungi, and viruses. Understanding how disease resistance works may ... study published online this week in the open-access journal ... how one aspect of the plant immune system is ...
... and separate a wide class of swimming bacteria ... at Argonne National Laboratory, Illinois Institute of technology, ... UK. This device could have enormous applications in ... medical diagnostic kits and bioanalysis. , The technique ...
... person, it triggers a series of biochemical reactions in immune-system ... , Usually, the result is an effective immune response, leading ... recovery. But in the case of some of the world’s ... as well as the influenza virus strain responsible for the ...
Cached Biology News:Researchers develop technique for bacteria crowd control 2New study may show how to forestall a fatal, virus-caused immune-system meltdown 2New study may show how to forestall a fatal, virus-caused immune-system meltdown 3
... Coating Stabilizer has been developed specifically ... immobilized proteins on microwell plates/strips. ... activity of the antibody or protein ... components. Product is filtered at ...
... Novagen's HT96 Isothermal Block is an ... hold HT96 plates and to provide efficient ... plate. This new design of the HT96 ... offers an enhanced product design allowing for ...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Biology Products: